Targeting apoptosis in prostate cancer

Hematology/Oncology Clinics of North America

Volumn 15, Issue 3, 2001, Pages 509-524

  DiPaola, Robert S ^a   Patel, Jignesh ^a   Rafi, Mohamed M ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS INHIBITOR; BCL 2 ANTISENSE; CASPASE; CYTOCHROME C; DACARBAZINE; DOCETAXEL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FAS ANTIBODY; GENE PRODUCT; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; MONOCLONAL ANTIBODY; PACLITAXEL; PHOSPHATIDYLINOSITIDE KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOIC ACID; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CLINICAL TRIAL; DNA DAMAGE; DNA VECTOR; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR GROWTH;

EID: 0034893968     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70229-X     Document Type: Article

References (89)

1. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
2. Cancer statistics 1997
3. NF-kappaB ten years after
4. An apoptosis-inhibiting gene from a nuclear polyhedrosis encoding a polypetide with Cys/His sequence motifs
5. Taxol induced apoptosis and phosphorylation of bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway
6. Proteins regulating ras and its relatives
7. p53 is mutated in a subset of advanced-stage prostate cancers
8. Ras oncogenes in human cancer: A review
9. Dominant-negative p53 mutations selected in yeast hit cancer hot spots
10. Interferon-B treatment of metastatic prostate cancer
11. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer
12. Phase I study and pharmacokinetics of weekly high dose 13-cis-retinoic acid
13. Ras gene mutations in human prostate cancer
14. Bcl-2 blocks p53-dependent apoptosis
15. Ras proto-oncogene activation in human malignancy
16. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers
17. Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid
18. Cellular survival: A play in three Akts
19. Wild type p53 mediates apoptosis by E1A which is inhibited by E1B
20. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases
21. IAP family proteins - Suppressors of apoptosis
22. X-linked IAP is a direct inhibitor of cell death proteases
23. Phase I clinical and pharmacologic study of 13-cis retinoic acid, alpha interferon and paclitaxel in patients with prostate cancer and other advanced malignancies
24. Effect of 13-cis retinoic acid and alpha interferon on transforming growth factor Beta1 in patients with rising prostate specific antigen
25. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
26. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells
27. Inactivation of bel-2 by phosphorylation
28. Phase I trial of bleomycin and trifluoperazine in treatment of malignant diseases
29. Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents
30. Bak BH3 peptides antagonize BCL-XL function and induce apoptosis through cytochrome-c independent activation of caspases
31. Regulation of the synthesis of bcl-2 protein by growth factors
32. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins
33. Independent induction of p2lwafl and apoptosis by all-trans-retinoic acid and 9-cis-retinoic acid in human prostate cancer cell lines
34. Wild-type p53 suppresses growth of human prostatic cancer cells containing mutant p53 alleles
35. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
36. Systemic treatment with bcl-2 antisense down-regulates tumor content of bcl-2 protein and induces major antitumor responses in patients with melanoma when combined with dacarbazine
37. Oncogenic forms of p53 inhibit p53-regulated gene expression
38. Pharmacology of 13-cis-retinoic acid in humans
39. How proteolysis drives the cell cycle
40. Comparison of ras activation in prostate carcinoma in Japanese and American men
41. Bcl-2 gene family and the regulation of programmed cell death
42. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers
43. Current chemotherapy and future directions in research for the treatment of advanced hormone-refractory prostate cancer
44. Apoptosis: Therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer
45. p53, the cellular gatekeeper for growth and division
46. Synergistic antitumor effects of a combination of interferon and retinoic acid on human tumor cells in vitro and in vivo
47. 13-Cis-retinoic acid plus interferon-2alpha: Highly active systemic therapy for squamous cell carcinoma of the cervix
48. 13-Cis-retinoic acid and interferon-2a: Effective combination therapy for advanced squamous cell carcinoma of the skin
49. Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
50. P53-dependent apoptosis modulates the cytotoxicity of anticancer agents
51. Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: Anti-angiogenic effect on HPV-harboring tumo-cell lines
52. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line
53. Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53 dependent apoptosis
54. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
55. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity
56. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
57. Effects of bromocriptine on prolactin secreting pituitary adenomas: Mechanism of reduction in tumor size evaluated by light and electron microscopic, immunohistochemical and morphometric analysis
58. Wild-type p53 negatively regulates the expression of a microtubule-associated protein
59. Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer
60. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma
61. NFk-B activation by tumour necrosis factor requires the Akt serine-threonine kinase
62. Phase I study of PS-341, a novel proteasome inhibitor, in patients with advanced malignancies
63. ras proteins and their GTPase activating proteins
64. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
65. Lamin proteolysis facilitates nuclear events during apoptosis
66. Bcl-2 family proteins: Regulators of apoptosis and chemoresistance in hematologic malignancies
67. Taxol in advanced hormone refractory carcinoma of the prostate
68. The HPV-16 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
69. A phase I trial of G3139, a bcl-2 anti-sense drug, by continuous infusion as a single agent and with weekly taxol
70. Three human transferring genes are related to the viral oncogenes
71. Interferon-gamma and monoclonal antibody 131I-labeled CC49: Outcomes in patients with androgen-independent prostate cancer
72. Retinoids in cancer therapy
73. The expression of drug resistance gene products during the progression of human prostate cancer
74. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene
75. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines
76. Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma
77. Combination adriamycin and suramin induces apoptosis in bc-2 expressing prostate carcinoma cells
78. Bcl-2 proteins: Regulators of apoptosis or of mitochondrial homeostasis?
79. A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer
80. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis
81. NF-kB antiapoptosis: Induction of TRAF-1 and TRAF-2 and cIAP1 and cIAP2 to suppress caspase-8 activation
82. Cell permeable Bcl-2 binding peptides: A chemical approach to apoptosis induction in tumor cells
83. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
84. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
85. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway
86. Restoration of taxol sensitivity in a p53 mutant, bcl-2 overexpressing cell line by interferon-alpha and retinoic acid
87. Influence of mutations in the transcriptional regulation domain of p53 on drug sensitivity
88. The prosurvival BCL-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNF-alpha induced apoptosis